Guidance, NICE advice and quality standards in development

Showing 341 to 350 of 372

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]	Technology appraisal guidance	TBC
Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessment	Health technology evaluation	TBC
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]	Technology appraisal guidance	TBC
Treatments for non-small-cell lung cancer [ID6234]	Technology appraisal guidance	TBC
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]	Technology appraisal guidance	24 July 2024
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]	Technology appraisal guidance	TBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]	Technology appraisal guidance	25 September 2024
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]	Technology appraisal guidance	TBC
Type 2 diabetes in adults: management (medicines update)	NICE guideline	19 June 2025
Ublituximab for treating relapsing–remitting multiple sclerosis ID6350	Technology appraisal guidance	TBC